公开(公告)号：US20210395836A1

公开(公告)日：2021-12-23

申请号：US17383390

申请日：2021-07-22

申请人： GUARDANT HEALTH, INC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Scott KOPETZ ,  AmirAli TALASAZ

IPC分类号： C12Q1/6886 ,  C07K16/28 ,  C07K16/30 ,  G16B99/00 ,  C07K14/71 ,  C07K14/82 ,  G16B20/20 ,  G16B20/10

摘要： Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.

公开(公告)号：US10934333B2

公开(公告)日：2021-03-02

申请号：US16915745

申请日：2020-06-29

申请人： Immatics Biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC分类号： C07K14/47 ,  A61K35/17 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10921311B2

公开(公告)日：2021-02-16

申请号：US16070110

申请日：2017-01-13

申请人： JAPANESE FOUNDATION FOR CANCER RESEARCH

发明人： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC分类号： C07H21/04 ,  C12Q1/68 ,  G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62 ,  C12Q1/6886 ,  C12Q1/6853 ,  C12Q1/686

摘要： It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20200378972A1

公开(公告)日：2020-12-03

申请号：US16989125

申请日：2020-08-10

申请人： Quest Diagnostics Investments LLC

发明人： Maher ALBITAR

IPC分类号： G01N33/574 ,  A61K31/497 ,  A61K31/506 ,  C07K14/82 ,  C12Q1/6883 ,  C12N9/12

摘要： A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

公开(公告)号：US20200325212A1

公开(公告)日：2020-10-15

申请号：US16559561

申请日：2019-09-03

申请人： City of Hope ,  Thomas Jefferson University

发明人： John C. WILLIAMS ,  Ulrich RODECK ,  Kurt JENKINS

IPC分类号： C07K14/82 ,  C07K16/28 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C12N9/64

摘要： Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neuro-degenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).

公开(公告)号：US20200261500A1

公开(公告)日：2020-08-20

申请号：US15929513

申请日：2020-05-06

申请人： Triumvira Immunologics USA, Inc. ,  McMaster University

发明人： Jonathan Lorne BRAMSON ,  Christopher W. HELSEN ,  Joanne Alicia HAMMILL ,  Kenneth Anthony MWAWASI

IPC分类号： A61K35/17 ,  C07K14/82 ,  A61P35/00 ,  C07K14/725

摘要： A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

公开(公告)号：US20200247869A1

公开(公告)日：2020-08-06

申请号：US16838395

申请日：2020-04-02

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services

发明人： Eric Tran ,  Yong-Chen Lu ,  Anna Pasetto ,  Paul F. Robbins ,  Steven A. Rosenberg ,  Zhili Zheng

IPC分类号： C07K14/725 ,  C12N15/85 ,  A61P35/00 ,  G01N33/574 ,  C07K14/82

摘要： Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

公开(公告)号：US20200222464A1

公开(公告)日：2020-07-16

申请号：US16742082

申请日：2020-01-14

申请人： TAIGA BIOTECHNOLOGIES, INC.

发明人： Brian Curtis TURNER ,  Yosef REFAELI ,  Gregory Alan BIRD

IPC分类号： A61K35/17 ,  C07K14/82 ,  A61K39/395 ,  C07K14/47 ,  C07K14/725 ,  C07K14/73 ,  C07K14/705 ,  C12N5/0783

摘要： This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.

公开(公告)号：US10711053B2

公开(公告)日：2020-07-14

申请号：US14711494

申请日：2015-05-13

申请人： Chemical & Biopharmaceutical Laboratories of Patras SA

发明人： Kleomenis Barlos ,  Konstantinos Barlos

IPC分类号： A61K38/28 ,  C07K14/62 ,  A61K38/30 ,  C07K14/65 ,  C07K14/64 ,  A61K38/12 ,  A61K38/16 ,  A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/82 ,  C07K1/107 ,  C07K1/113

摘要： It is described the preparation of Insulin like peptides, of chimeric Insulin like peptides and of their derivatives by the random combination of their chains A and their chains B and the pharmaceutical application of the obtained products.

公开(公告)号：US10596239B2

公开(公告)日：2020-03-24

申请号：US15716861

申请日：2017-09-27

申请人： TARGOVAX ASA

发明人： Jon Amund Eriksen

IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/82 ,  G01N33/50 ,  A61K35/17 ,  G01N33/483

摘要： There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.